Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18446 | 0.89 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL16811766 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL1857628 | 0.80 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL2945943 | 0.80 | GAA (0.46) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL2948744 | 0.79 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL2941847 | 0.78 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL7208877 | 0.78 | ALOX15 (0.50) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL16811720 | 0.78 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL16811738 | 0.78 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL125810 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| EP-3409671-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-21 | — | — | EP | disclosed |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICALS NV (BE) | 2020-04-14 | — | — | US | disclosed |
| CN-106414434-B | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes | 詹森药业有限公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190071435-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-07 | — | — | US | disclosed |
| EP-3409671-A1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica NV (BE) | 2018-12-05 | — | — | EP | disclosed |
| US-10118922-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| EP-3114123-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-25 | — | — | EP | disclosed |
| US-20170104160-A1 | ORGANIC SEMICONDUCTING COMPOUNDS AND RELATED OPTOELECTRONIC DEVICES | USINVEST LLC | 2017-04-13 | — | — | US | disclosed |
| CN-106414434-A | Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes | 詹森药业有限公司 | 2017-02-15 | — | — | CN | disclosed |
| US-20140024652-A1 | SUBSTITUTED TRIAZOLOPHTHALAZINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8557815-B2 | Substituted triazolophthalazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557815-B2 | Substituted triazolophthalazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20110172235-A1 | SUBSTITUTED TRIAZOLOPHTHALAZINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011020044-A1 | SUBSTITUTED TRIAZOLOPHTHALAZINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | WO | disclosed |
| US-6737429-B2 | TREATMENT OF HIV MEDIATED DISEASES. | HOFFMANN-LA ROCHE INC. | 2004-05-18 | — | — | US | disclosed |
| EP-1301481-A1 | PYRROLE DERIVATIVES FOR TREATING AIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-16 | — | — | EP | disclosed |
| US-20020032221-A1 | Pyrrole derivatives | ROCHE PRODUCTS LIMITED (GB) | 2002-03-14 | — | — | US | disclosed |
| WO-2002002524-A1 | PYRROLE DERIVATIVES FOR TREATING AIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071435-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GLP1R, GCGR | ALDH1A1 1789/4885LMNA 3323/4885HSD17B10 1592/4885 |
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, FABP1, EIF2AK2 | ALDH1A1 2132/4885LMNA 3769/4885HSD17B10 1274/4885 |
| US-10118922-B2 | GPR120 agonists for the treatment of type II diabetes | GPR119, GLP1R, GCGR | ALDH1A1 1789/4885LMNA 3323/4885HSD17B10 1592/4885 |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, USP8, USP7 | ALDH1A1 2350/4885LMNA 2679/4885HSD17B10 3640/4885 |
| US-20110172235-A1 | SUBSTITUTED TRIAZOLOPHTHALAZINE DERIVATIVES | GPR55, HTR5A, GRK5 | ALDH1A1 2452/4885LMNA 4135/4885HSD17B10 2973/4885 |
| US-20170104160-A1 | ORGANIC SEMICONDUCTING COMPOUNDS AND RELATED OPTOELECTRONIC DEVICES | AQP4, EPCAM, ORAI2 | ALDH1A1 2198/4885LMNA 2551/4885HSD17B10 3907/4885 |
| US-20020032221-A1 | Pyrrole derivatives | PYCR1, SARS1, MAVS | ALDH1A1 2902/4885LMNA 4545/4885HSD17B10 1714/4885 |
| US-20140024652-A1 | SUBSTITUTED TRIAZOLOPHTHALAZINE DERIVATIVES | GPR55, HTR5A, GRK5 | ALDH1A1 2452/4885LMNA 4135/4885HSD17B10 2973/4885 |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | GPR119, GLP1R, GCGR | ALDH1A1 1789/4885LMNA 3323/4885HSD17B10 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.